Filing Flows › Onconetix (ONCO) › Q2 2026
Onconetix (ONCO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Onconetix (ONCO) reported revenue of $17K for the second quarter 2026 (Q2 2026), -84% from a year earlier and -20% from the quarter before.
Onconetix, Q2 2026: revenue $17K (-84% year over year), net loss $2.9M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17K | -20% | -84% |
| Operating profit | −$2.7M | — | — |
| Net earnings | −$2.9M | — | — |
| Operating cash flow | −$1.9M | — | — |
What changed
Revenue was $17K in Q2 2026, down 84% year over year and down 20% from the previous quarter.
Gross margin was 25.1%, down 41.1 points from Q2 2025. Operating costs exceeded revenue by $2.7M, an operating margin of -15950.9%. Operating expenses grew 36% against a revenue fall of 84%. The fastest-growing cost line was SG&A (+47%). The quarter ended with a net loss of $2.9M, narrower than the previous quarter's $4.2M loss.
Operating cash flow was −$1.9M. Non-cash charges added back $3K of depreciation and amortization and $7K of share-based compensation. Working capital and other items added $939K.
Questions
What was Onconetix's revenue in the second quarter 2026?
Onconetix (ONCO) reported revenue of $17K for the second quarter 2026 (Q2 2026), -84% from a year earlier and -20% from the quarter before.
Source: Onconetix 10-Q on SEC EDGAR.